MORF-057: Completion of P2 EMERALD-2 trial (NCT03157128) for ulcerative colitis in Aug 2026 (Eli Lilly) - May 1, 2025 - Q1 2025 Results: Primary completion of P2 GARNET trial (NCT03157128) for ulcerative colitis in May 2026; Completion of P2 GARNET trial for Crohn's disease in June 2028
Trial completion date • Trial primary completion date • Crohn's disease • Inflammatory Bowel Disease • Ulcerative Colitis
|